Author

Yuhan Liu

Institutions: Harbin University of Commerce, Third Affiliated Hospital of Harbin Medical University

Observed institutions: Harbin Medical University, Beijing University of Chinese Medicine, Dalian University of Technology, Liaoning University of Traditional Chinese Medicine, Peking Union Medical College Hospital, Harbin University of Commerce, Third Affiliated Hospital of Harbin Medical University

ORCID: 0000-0001-9480-7005

Observed ORCID: 0000-0001-9480-7005

OpenAlex ID: A5088209743

The Rhei radix rhizoma -based carbon dots ameliorates dextran sodium sulphate-induced ulcerative colitis in mice

2023 · Yifan Zhang, Jie Zhao, et al. · Artificial Cells Nanomedicine and Biotechnology · 25

Tetrandrine and adriamycin reverse multidrug resistance by regulating NLRP3/Caspase-1/GSDMD signaling in human breast cancer cells

2025 · Guosong Xin, Yanxiu Hou, et al. · European Journal of Pharmacology · 10

PSMD14 promotes breast cancer progression by reducing K63-linked ubiquitination on FOXM1 and activating the PI3K/AKT/mTOR pathway

2025 · Yuhan Liu, Shichao Wen, et al. · International Journal of Biological Macromolecules · 9

Enterolactone combined with m6A Reader IGF2BP3 inhibits malignant angiogenesis and disease progression in ovarian cancer

2024 · Mengzhi Xu, Yi Guo, et al. · Phytomedicine · 9

Metabonomics and pharmacodynamics studies of Gentiana radix and wine-processed Gentiana radix in damp-heat jaundice syndrome rats

2024 · Xin Lv, Yangzhi Liu, et al. · Journal of Ethnopharmacology · 6

Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial

2024 · Changjun Wang, Yan Lin, et al. · eLife

Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial

2024 · Changjun Wang, Yan Lin, et al. · eLife

Different treatment durations of loperamide in preventing pyrotinib-induced diarrhea: A randomized, parallel-group sub-study of the phase II PHAEDRA trial

2024 · Changjun Wang, Yan Lin, et al. · medRxiv

Works count: 8

Citation count: 59

H-index: 5

I10-index: 2